ID Source | ID |
---|---|
PubMed CID | 6433761 |
CHEMBL ID | 2104135 |
CHEBI ID | 135478 |
SCHEMBL ID | 25139 |
SCHEMBL ID | 25138 |
MeSH ID | M0062012 |
Synonym |
---|
5-methoxy-2-methyl-1-(1-oxo-3-phenyl-2-propenyl)-1h-indole-3-acetic acid |
cinmetacina [inn-spanish] |
1h-indole-3-acetic acid, 5-methoxy-2-methyl-1-(1-oxo-3-phenyl-2-propenyl)- |
cinmetacinum [inn-latin] |
cinmetacin |
cinmetacin [inn] |
einecs 243-555-6 |
cinmetacine [inn-french] |
indolacin |
1-cinnamoyl-5-methoxy-2-methylindole-3-acetic acid |
cindomet |
1-cinnamoyl-2-methyl-5-methoxy-3-indolylacetic acid |
indole-3-acetic acid, 1-cinnamoyl-5-methoxy-2-methyl- |
cinmethacin |
CHEBI:135478 |
2-[5-methoxy-2-methyl-1-[(e)-3-phenylprop-2-enoyl]indol-3-yl]acetic acid |
CHEMBL2104135 |
3zli4719j9 , |
unii-3zli4719j9 |
881743-37-9 |
1h-indole-3-acetic acid, 5-methoxy-2-methyl-1((2e)-1-oxo-3-phenyl-2-propen-1-yl) |
cinmetacine |
1-cinnamoyl-5-methoxy-2-methyl-3-indolylessigsaeure |
cinmetacinum |
cinmetacina |
s 1290 |
20168-99-4 |
tvx 1764 |
cinmetacin [mart.] |
cinmetacin [who-dd] |
cinmetacin [mi] |
1h-indole-3-acetic acid, 5-methoxy-2-methyl-1-((2e)-1-oxo-3-phenyl-2-propen-1-yl)- |
SCHEMBL25139 |
SCHEMBL25138 |
(2-amino-2-iminoethyl)phenylmethylcarbamicacid ester,monohydrochloride |
Q27258257 |
DTXSID00864922 |
5-methoxy-2-methyl-1-[(2e)-1-oxo-3-phenyl-2-propen-1-yl]-1h-indole-3-acetic acid |
1h-indole-3-acetic acid, 5-methoxy-2-methyl-1-(1-oxo-3-phenyl-2-propen-1-yl)- |
Excerpt | Reference | Relevance |
---|---|---|
" Following administration, the Cmax was reached at the 2nd h in 7 out of 8 subjects with an average value of 18." | ( Plasma pharmacokinetics of cinmetacin following oral administration in healthy volunteers. Acerbi, D; Danesi, R; Del Tacca, M; Ducci, M, 1988) | 0.27 |
Class | Description |
---|---|
indole-3-acetic acids | An indol-3-yl carboxylic acid in which the carboxylic acid specified is acetic acid. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 3 (60.00) | 18.7374 |
1990's | 2 (40.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 2 (40.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 3 (60.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |